Literature DB >> 31970497

PIK3CA mutations and specific treatment: do not forget lessons from RAS mutations and EGFR targeting.

Gérard Milano1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31970497     DOI： 10.1007/s00280-019-04016-9

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


× No keyword cloud information.
  2 in total

1.  Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors.

Authors:  Pedram Razavi; Jared L Johnson; Hong Shao; Neil Vasan; Hardik Shah; Alesia Antoine; Erik Ladewig; Alexander Gorelick; Ting-Yu Lin; Eneda Toska; Guotai Xu; Abiha Kazmi; Matthew T Chang; Barry S Taylor; Maura N Dickler; Komal Jhaveri; Sarat Chandarlapaty; Raul Rabadan; Ed Reznik; Melissa L Smith; Robert Sebra; Frauke Schimmoller; Timothy R Wilson; Lori S Friedman; Lewis C Cantley; Maurizio Scaltriti; José Baselga
Journal:  Science       Date:  2019-11-08       Impact factor: 47.728

Review 2.  Advances and perspectives of PARP inhibitors.

Authors:  Ming Yi; Bing Dong; Shuang Qin; Qian Chu; Kongming Wu; Suxia Luo
Journal:  Exp Hematol Oncol       Date:  2019-11-11
  2 in total
  1 in total

1.  Biosensors for Point Mutation Detection.

Authors:  Hanlin Jiang; Hui Xi; Mario Juhas; Yang Zhang
Journal:  Front Bioeng Biotechnol       Date:  2021-12-15
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.